<DOC>
	<DOCNO>NCT01299220</DOCNO>
	<brief_summary>This study look low-dose regimen acitretin helpful treat skin rash cause chemotherapy drug , erlotinib .</brief_summary>
	<brief_title>Study Acitretin Treat Skin Rash Caused Erlotinib ( Chemotherapy Drug )</brief_title>
	<detailed_description>This pilot trial initial target sample 32 evaluable subject . The study last 12 week per subject 9 month entire study . Cancer patient begin antineoplastic therapy EGFR inhibitor erlotinib enrol trial . Patients begin erlotinib therapy simultaneously initiate skin care regimen consist twice daily application Eucerin , TM Aveeno , TM CeraveTM moisturize cream daily application SPF 15 great sunscreen . Those patient develop rash CTCAE Grade 2 high refer u primary oncologist . Upon onset cutaneous eruption , oncologist initiate therapy doxycycline ( 100 mg twice daily ; allergic doxycycline instead receive cephalexin , 250 mg twice daily ) . On evaluation Principal Investigator , patient insufficient response two week course doxycycline ( continued CTCAE Grade 2 high rash ) begin therapy low-dose acitretin ( 10 mg/day ) . Patients continue receive 10 mg/day acitretin follow 12 week , treat off-study accord individualized regimen agree upon patient treat oncologist . Patients continue unacceptable skin eruption require off-study dose reduction interruption erlotinib despite acitretin treatment , well patient develop CTCAE Grade 3 high toxicity presumptively due acitretin , consider non-responders study . These patient treat off-study .</detailed_description>
	<mesh_term>Exanthema</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>18 year age old time study enrollment . Started routine clinical , palliative , experimental ( offlabel ) treatment erlotinib solid tumor develop Grade 2 high skin toxicity base National Cancer Institute Common Terminology Criteria Adverse Events ( CTCAE ) version 4.02 . Failed therapy twoweek course antibiotic ( doxycycline 100 mg twice daily , cephalexin 250 mg twice daily patient allergic doxycycline ) . Willing able provide verbal write informed consent If reproductive potential , male female , must practice effective contraceptive measure throughout study . Women childbearing potential must provide negative pregnancy test ( serum urine ) within 14 day prior enrollment . Pregnant breastfeeding female . Known suspect sensitivity study medication . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 3 worse . Treatment nonapproved investigational drug ( exception erlotinib use experimental setting ) within 30 day prior Day 1 study treatment . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness . Bilirubin great equal three time upper limit normal . Sexually active woman childbearing potential must use effective method birth</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Erlotinib</keyword>
	<keyword>Acitretin</keyword>
	<keyword>Rash</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Oncology</keyword>
</DOC>